OTC Pharmaceuticals Report - 2019

Statista Consumer Market Outlook - Market Report

OTC Pharmaceuticals Report - 2019 The steady improvement in human development and access to medicines will continue to impact the OTC Pharmaceuticals market. Overall, the OTC Pharmaceuticals market realized a revenue of US$110 billion worldwide. With US$84 per capita, the Swiss spent the most on OTC Pharmaceuticals in 2018, followed by Australia and United States. In this report, growth potentials, market drivers, consumer insights, key companies and future developments for three major OTC Pharmaceuticals markets, North America, Europe and Asia, will be discussed.

What's included?
  • Market Overview and all relevant sales figures
  • Consumer insights and trends
  • Sales channels
  • Key players - Johnson & Johnson, GlaxoSmithKline, Bayer AG
  • Segment deep dives
  • KPI comparison: Sales and growth rates
  • Country and regional comparison
  • Market forecasts

The Over-the-counter (OTC) Pharmaceuticals market comprises prescription-free medicines. They are common treatment for physicians and patients when it comes to minor diseases. The market is divided into five segments: Analgesics, Cough & Cold Remedies, Digestives & Intestinal Remedies, Skin Treatment and Vitamins & Minerals.

This report from the series of Consumer Market Outlook reports gives an overview of the OTC Pharmaceuticals market from an international perspective. Besides all relevant market figures like total and per capita revenues for the years from 2012 to 2023, we furthermore give detailed insights into current trends, key players and important background information on the OTC Pharmaceuticals market.

In general, the OTC Pharmaceuticals market is expected to grow at a CAGR of 3% between 2012 and 2023. All segments within the OTC Pharmaceuticals market are growing by more than 10% between 2018 and 2023. Particularly strong growth is expected in middle-income countries, as the infrastructure is being further expanded. But over-the-counter pharmaceuticals will continue to show high positive growth in OECD countries as well, as patients often receive preventive services. However, the Cold & Cough Remedies segment shows the highest growth potential and is expected to increase by 25%, reaching US$41 billion in 2023. The Cough & Cold Remedies and Analgesics segments together account for more than half of total revenue, especially due to the major sales of Aspirin, Paracetamol, Ibuprofen, and remedies against flu-like infections.

Note: CAGR: Compound Annual Growth Rate / average growth rate per year

  • Language: English
  • Released: May 2019
More than 7,500
Recommended studies and dossiers
Show more
Recent studies and dossiers
You may also be interested in...
Statista is a great source of knowledge, and pretty helpful to manage the daily work.

Christof Baron about Statista CEO, MindShare Germany

Any more questions?

Get in touch with us quickly and easily.
We are happy to help!